Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX): 6 pipeline candidates · ~20 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
20.0 months
D/E 1.05 · 5% dilution
Lead: Phase 2
6 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Lineage Cell Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$306.6M
Cash
$36.5M
Quarterly Burn
$8.1M
Runway
20.0 mo
Revenue
$1.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
131
Total value held
$189.0M
| Holder | Shares | Value |
|---|---|---|
| broadwood capital inc | 49,560,992 | $78.3M |
| vanguard capital management llc | 16,637,370 | $26.3M |
| defender capital, llc. | 6,729,599 | $10.6M |
| millennium management llc | 5,561,374 | $8.8M |
| raffles associates lp | 5,362,788 | $8.5M |
| fifth third bancorp | 4,600,000 | $7.3M |
| blackrock, inc. | 3,864,757 | $6.1M |
| armistice capital, llc | 3,182,799 | $5.0M |
| marshall wace, llp | 3,065,033 | $4.8M |
| geode capital management, llc | 2,523,114 | $4.0M |
Showing top 10 of 131 institutional holders of Lineage Cell Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Lineage Cell Therapeutics, Inc.'s pipeline?
Lineage Cell Therapeutics, Inc. (LCTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Lineage Cell Therapeutics, Inc.'s lead drug candidate?
Lineage Cell Therapeutics, Inc.'s most advanced tracked candidate is ilt1 (Preclinical) for Type 1 Diabetes (T1D).
What is Lineage Cell Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Lineage Cell Therapeutics, Inc. has approximately 20.0 months of cash runway.
What is Lineage Cell Therapeutics, Inc.'s market capitalization?
Lineage Cell Therapeutics, Inc.'s market capitalization is approximately $306.6M.
Who is the CEO of Lineage Cell Therapeutics, Inc.?
Mr. Brian M. Culley M.A., M.B.A. is the chief executive officer of Lineage Cell Therapeutics, Inc. (LCTX).
Get the full picture on Lineage Cell Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.